Spectral extension of the quantum group cotangent bundle

The structure of a cotangent bundle is investigated for quantum linear groups GLq(n) and SLq(n). Using a q-version of the Cayley-Hamilton theorem we construct an extension of the algebra of differential operators on SLq(n) (otherwise called the Heisenberg double) by spectral values of the matrix of right invariant vector fields. We consider two applications for the spectral extension. First, we describe the extended Heisenberg double in terms of a new set of generators -- the Weyl partners of the spectral variables. Calculating defining relations in terms of these generators allows us to derive SLq(n) type dynamical R-matrices in a surprisingly simple way. Second, we calculate an evolution operator for the model of q-deformed isotropic top introduced by A.Alekseev and L.Faddeev. The evolution operator is not uniquely defined and we present two possible expressions for it. The first one is a Riemann theta function in the spectral variables. The second one is an almost free motion evolution operator in terms of logarithms of the spectral variables. Relation between the two operators is given by a modular functional equation for Riemann theta function.Comment: 38 pages, no figure

Severe rhinovirus bronchiolitis in premature infant with bronchopulmonary dysplasia

Acute bronchiolitis is an inflammatory disease of the lower respiratory tract with a predominant lesion of small bronchi and bronchioles developing in children under 2 years of age. The main etiological factor of bronchiolitis is the respiratory syncytial virus (RSV), the second place in the etiologic structure belongs to rhinovirus, which causes bronchiolitis usually at 6 months age. Severe bronchiolitis is characterized by the need for auxiliary or artificial lung ventilation (ALV). The main risk groups for severe bronchiolitis include premature infants with or without bronchopulmonary dysplasia (BPD), children with hemodynamically significant congenital heart defects. The article presents a clinical observation of rhinovirus bronchiolitis severe course in a preterm infant aged 4,5 months (post-conceptual age-42 weeks) with severe BPD manifesting with an apnea episode followed by the development of severe respiratory failure requiring mechanical ventilation accompanied by sinus tachycardia. The study demonstrates the possibility of acute bronchiolitis severe course in a premature infant with BPD, not only because of RSV infection, but with rhinovirus infection in the first half of life, which should be considered during virus examination. © 2017, Pediatria Ltd. All rights reserved

Severe rhinovirus bronchiolitis in premature infant with bronchopulmonary dysplasia

Acute bronchiolitis is an inflammatory disease of the lower respiratory tract with a predominant lesion of small bronchi and bronchioles developing in children under 2 years of age. The main etiological factor of bronchiolitis is the respiratory syncytial virus (RSV), the second place in the etiologic structure belongs to rhinovirus, which causes bronchiolitis usually at 6 months age. Severe bronchiolitis is characterized by the need for auxiliary or artificial lung ventilation (ALV). The main risk groups for severe bronchiolitis include premature infants with or without bronchopulmonary dysplasia (BPD), children with hemodynamically significant congenital heart defects. The article presents a clinical observation of rhinovirus bronchiolitis severe course in a preterm infant aged 4,5 months (post-conceptual age-42 weeks) with severe BPD manifesting with an apnea episode followed by the development of severe respiratory failure requiring mechanical ventilation accompanied by sinus tachycardia. The study demonstrates the possibility of acute bronchiolitis severe course in a premature infant with BPD, not only because of RSV infection, but with rhinovirus infection in the first half of life, which should be considered during virus examination. © 2017, Pediatria Ltd. All rights reserved

Brain–lung–thyroid syndrome: Literature review and series of clinical observations

Brain–lung–thyroid syndrome (BLTS) is a rare genetic disease associated with mutations in the NKX2.1 gene encoding thyroid transcription factor 1. The most common manifestations of this syndrome are benign hereditary chorea, hypothyroidism and respiratory distress syndrome, however, mutations in the NKX2.1 gene can also cause other pathologies of nervous, respiratory systems and thyroid gland. The article describes 4 patients with mutations in the NKX2.1 gene observed by authors. Based on the analysis of the observations of 168 patients with BLTS presented in the world literature from 1998 to 2019, current information on the genetics, pathogenesis, clinical X-ray manifestations, outcomes and treatment of the syndrome are summarized. © 2019, Pediatria Ltd. All rights reserved

Синдром "мозг-легкие-щитовидная железа": обзор литературы и серия клинических наблюдений

Brain-lung-thyroid syndrome (BLTS) is a rare genetic disease associated with mutations in the NKX2.1 gene encoding thyroid transcription factor 1. The most common manifestations of this syndrome are benign hereditary chorea, hypothyroidism and respiratory distress syndrome, however, mutations in the NKX2.1 gene can also cause other pathologies of nervous, respiratory systems and thyroid gland. The article describes 4 patients with mutations in the NKX2.1 gene observed by authors. Based on the analysis of the observations of 168 patients with BLTS presented in the world literature from 1998 to 2019, current information on the genetics, pathogenesis, clinical X-ray manifestations, outcomes and treatment of the syndrome are summarized.Синдром «мозг-легкие-щитовидная железа» (СМЛЩЖ) - редкое генетическое заболевание, ассоциированное с мутациями в гене NKX2.1, кодирующем тиреоидный фактор транскрипции-1. Наиболее частыми проявлениями данного синдрома являются доброкачественная наследственная хорея, гипотиреоз и респираторный дистресс-синдром, однако мутации в гене NKX2.1 могут быть причиной и другой патологии со стороны нервной, дыхательной систем и щитовидной железы. В статье представлено описание 4 пациентов с мутациями в гене NKX2.1, наблюдавшихся авторами. На основании анализа наблюдений 168 пациентов с СМЛЩЖ, представленных в мировой литературе с 1998 по 2019 гг., обобщены современные сведения о генетике, патогенезе, клинико-рентгенологических проявлениях, исходах и терапии синдрома

Palivizumab: Four seasons in Russia

In 2010, the Russian Federation (RF) registered palivizumab - innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization. © 2014, Izdatel'stvo Meditsina. All rights reserved

Palivizumab: Four seasons in Russia

In 2010, the Russian Federation (RF) registered palivizumab - innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization. © 2014, Izdatel'stvo Meditsina. All rights reserved

The structure of interstitial lung diseases in children of the first two years of life

For the first time in Russia, the article provides data on interstitial lung diseases structure in children of the first two years of life, based on a series of observations of 68 patients with these rare diseases, as a part of multi-center ambispective study. Interstitial lung diseases in observed children included: Wilson-Mikity syndrome (23,4%), neuroendocrine hyperplasia of infancy (22%), bronchiolitis obliterans with organizing pneumonia (7,4%), primary pulmonary hypoplasia (1,5%), secondary pulmonary hypoplasia with Jeune syndrome (10,3%), secondary pulmonary hypoplasia with Edwards syndrome (2,9%), secondary pulmonary hypoplasia with other associated pathology (omphalocele - 1,5%, non-immune fetal hydrops - 1,5%), subpleural cysts in patients with Down syndrome (5,9%), congenital deficiency of surfactant protein B (1,5%), brain-lung- thyroid syndrome (2,9%), congenital alveolar-capillary dysplasia (1,5%), interstitial lung diseases with systemic diseases (Langerhans cell histiocytosis - 16,2%, Niemann-Pick disease - 1,5%). The article summarizes clinical features, the results of image diagnosis and disease outcomes. © 2015, Pediatria Ltd. All rights reserved

The structure of interstitial lung diseases in children of the first two years of life

For the first time in Russia, the article provides data on interstitial lung diseases structure in children of the first two years of life, based on a series of observations of 68 patients with these rare diseases, as a part of multi-center ambispective study. Interstitial lung diseases in observed children included: Wilson-Mikity syndrome (23,4%), neuroendocrine hyperplasia of infancy (22%), bronchiolitis obliterans with organizing pneumonia (7,4%), primary pulmonary hypoplasia (1,5%), secondary pulmonary hypoplasia with Jeune syndrome (10,3%), secondary pulmonary hypoplasia with Edwards syndrome (2,9%), secondary pulmonary hypoplasia with other associated pathology (omphalocele - 1,5%, non-immune fetal hydrops - 1,5%), subpleural cysts in patients with Down syndrome (5,9%), congenital deficiency of surfactant protein B (1,5%), brain-lung- thyroid syndrome (2,9%), congenital alveolar-capillary dysplasia (1,5%), interstitial lung diseases with systemic diseases (Langerhans cell histiocytosis - 16,2%, Niemann-Pick disease - 1,5%). The article summarizes clinical features, the results of image diagnosis and disease outcomes. © 2015, Pediatria Ltd. All rights reserved